HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma

Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview

(2017) Alvaro Arjona-Sánchez et al.   World Journal of Gastrointestinal Oncology

“Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances”

(2016) A. Arjona-Sánchez et al.   EJSO

Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial

(2015) Charlotte E L Klaver et al.   BMC CANCER

Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review

(2014) D A M Sloothaak et al.   BRITISH JOURNAL OF CANCER

Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases

(2014) P. Sammartino et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands

(2014) Marloes A. G. Elferink et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

(2014) Arancha Prada-Villaverde et al.   JOURNAL OF SURGICAL ONCOLOGY

Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States

(2013) K. Turaga et al.   ANNALS OF SURGICAL ONCOLOGY

pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited

(2013) P. Snaebjornsson et al.   INTERNATIONAL JOURNAL OF CANCER

The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study

(2013) D. Hompes et al.   JOURNAL OF SURGICAL ONCOLOGY

Outcome of Patients with Aggressive Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy

(2013) Alvaro Arjona-Sanchez et al.   WORLD JOURNAL OF SURGERY

HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?

(2012) D. Hompes et al.   ANNALS OF ONCOLOGY

Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review

(2012) Charles Honoré et al.   ANNALS OF SURGICAL ONCOLOGY

Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis

(2011) D Elias et al.   ANNALS OF SURGERY

Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841

(2011) Jan Franko et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Intraperitoneal Chemotherapy with Mitomycin C on the Prevention of Peritoneal Recurrence in Colorectal Cancer Patients with Positive Peritoneal Lavage Cytology Findings

(2010) Shingo Noura et al.   ANNALS OF SURGICAL ONCOLOGY

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population-based study

(2010) Valery E. Lemmens et al.   INTERNATIONAL JOURNAL OF CANCER

Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion

(2008) Olivier Glehen et al.   JOURNAL OF SURGICAL ONCOLOGY